Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis
AstraZeneca
1,850 participants
Jun 25, 2024
OBSERVATIONAL
Conditions
Summary
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Eligibility
Inclusion Criteria4
- Patient willing and able to provide written informed consent to participate in the study
- Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
- Aged ≥18 years at the time of signing the informed consent
- Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)
Exclusion Criteria4
- Concurrent participation in any interventional trial for ATTR amyloidosis
- Involvement in the planning and/or conduct of the current study
- Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
- Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Data will be collected on patients with ATTR amyloidosis in a real-world setting
Locations(53)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06465810